Hvis en patient responderer dårligt på behandling med Rebif og har neutraliserende antistoffer, bør den ansvarlige læge reevaluere ratioen for fordele/ risici ved fortsat behandling.
If a patient responds poorly to therapy with Rebif, and has neutralising antibodies, the treating physician should reassess the benefit/ risk ratio of continued Rebif therapy.